UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Cancer discovery, 2015-05, Vol.5 (5), p.475-487

2015

Link zum Volltext

Verfügbarkeit prüfen

Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

Cancer cell, 2015-01, Vol.27 (1), p.97-108

2015

Link zum Volltext

Verfügbarkeit prüfen

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Science (American Association for the Advancement of Science), 2014-12, Vol.346 (6216), p.1480-1486

2014

Link zum Volltext

Verfügbarkeit prüfen

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction

Molecular oncology, 2020-10, Vol.14 (10), p.2504-2519

2020

Link zum Volltext

Verfügbarkeit prüfen

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer

Cancer discovery, 2016-07, Vol.6 (7), p.754-769

2016

Link zum Volltext

Verfügbarkeit prüfen

MYCN -Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis

Cancer research (Chicago, Ill.), 2021-04, Vol.81 (7), p.1896-1908

2021

Link zum Volltext

Verfügbarkeit prüfen

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

Proceedings of the National Academy of Sciences - PNAS, 2013-12, Vol.110 (52), p.21124-21129

2013

Link zum Volltext

Verfügbarkeit prüfen

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

The Journal of clinical investigation, 2008-07, Vol.118 (7), p.2609-2619

2008

Link zum Volltext

Verfügbarkeit prüfen

Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer

The Journal of experimental medicine, 2018-03, Vol.215 (3), p.895-910

2018

Link zum Volltext

Verfügbarkeit prüfen

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

Cancer discovery, 2011-09, Vol.1 (4), p.352-365

2011

Link zum Volltext

Verfügbarkeit prüfen

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

Proceedings of the National Academy of Sciences - PNAS, 2009-11, Vol.106 (46), p.19503-19508

2009

Link zum Volltext

Verfügbarkeit prüfen

Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment

International journal of molecular sciences, 2023-09, Vol.24 (17), p.13082

2023

Link zum Volltext

Verfügbarkeit prüfen

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

Proceedings of the National Academy of Sciences - PNAS, 2015-03, Vol.112 (11), p.E1288-E1296

2015

Link zum Volltext

Verfügbarkeit prüfen

Increased synthesis of MCL-1 protein underlies initial survival of EGFR mutant lung cancer to EGFR inhibitors and provides a novel drug target

Clinical cancer research, 2018-11, Vol.24 (22), p.5658-5672

2018

Link zum Volltext

Verfügbarkeit prüfen

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Cancer research (Chicago, Ill.), 2014-06, Vol.74 (11), p.3146-3156

2014

Link zum Volltext

Verfügbarkeit prüfen

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition

Cell reports (Cambridge), 2022-07, Vol.40 (4), p.111095-111095, Article 111095

2022

Link zum Volltext

Verfügbarkeit prüfen

Activation of PI3K Signaling in Merkel Cell Carcinoma

Clinical cancer research, 2012-03, Vol.18 (5), p.1227-1236

2012

Link zum Volltext

Verfügbarkeit prüfen

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors

Cell death & disease, 2021-02, Vol.12 (2), p.179-13, Article 179

2021

Link zum Volltext

Verfügbarkeit prüfen

Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Cancer science, 2014-05, Vol.105 (5), p.499-505

2014

Link zum Volltext

Verfügbarkeit prüfen

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer

Cancer letters, 2014-06, Vol.347 (2), p.204-211

2014

Link zum Volltext

Verfügbarkeit prüfen

Differences underlying EGFR and HER2 oncogene addiction

Cell cycle (Georgetown, Tex.), 2010-03, Vol.9 (5), p.851-852

2010

Link zum Volltext

Verfügbarkeit prüfen

Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA

Cancers, 2021-05, Vol.13 (10), p.2310

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(121)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Life Sciences & Biomedicine
(77)
Humans
(70)
Oncology
(40)
Animals
(32)
Cell Line, Tumor
(30)
Mice
(28)
Female
(27)
Apoptosis
(23)
Mutation
(22)
Tumors
(19)
Apoptosis - Drug Effects
(18)
Cell Biology
(17)
Male
(16)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Cancer Research
(13)
Protein Kinase Inhibitors - Pharmacology
(13)
Adult
(12)
Aged
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer

MYCN -Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

Increased synthesis of MCL-1 protein underlies initial survival of EGFR mutant lung cancer to EGFR inhibitors and provides a novel drug target

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition

Activation of PI3K Signaling in Merkel Cell Carcinoma

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors

Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer

Differences underlying EGFR and HER2 oncogene addiction

Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA

Suchergebnisse filtern